XML 64 R53.htm IDEA: XBRL DOCUMENT v3.8.0.1
Litigation (Details)
$ in Millions
3 Months Ended 9 Months Ended
Oct. 13, 2017
Jun. 30, 2017
USD ($)
Sep. 30, 2017
USD ($)
patent
Litigation      
Estimated loss contingency accrual expense | $     $ 210.0
Other current liabilities      
Litigation      
Loss contingency accrual, current | $   $ 210.0  
U.S. Department of Justice      
Litigation      
Estimated loss contingency accrual expense | $   210.0  
U.S. Department of Justice | Operating expenses      
Litigation      
Estimated loss contingency accrual expense | $   $ 210.0  
Pending Litigation | Watson Laboratories Inc.      
Litigation      
Maximum period for which the FDA is automatically precluded from approving ANDA     30 months
Number of additional patents being addressed in litigation | patent     2
Time period PTAB has to decided whether to institute IPR proceedings 3 months    
Time period after PTAB petitions resolution that litigation parties asked to stay case     14 days
Pending Litigation | Actavis Laboratories FL, Inc.      
Litigation      
Maximum period for which the FDA is automatically precluded from approving ANDA     30 months
Number of additional patents being addressed in litigation | patent     1
Number of patents on which district court decision is adverse | patent     9
Number of patents related to alleged infringement in second amended complaint by reporting entity | patent     2
Pending Litigation | SteadyMed Ltd.      
Litigation      
Number of days for supply of treprostinil under FDA approval     2 days